Mechanisms of acquired androgen independence during arsenic-induced malignant transformation of human prostate epithelial cells

Environmental Health Perspectives

Volumn 115, Issue 2, 2007, Pages 243-247

  Benbrahim Tallaa, Lamia ^a   Webber, Mukta M ^b,c   Waalkes, Michael P ^a  

^a National Cancer Institute   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Androgen receptor; Androgen independent; Arsenic; Cancer progression; Hormone refractory; Malignant transformation; MAP kinase; Prostate; Ras

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; A RAF KINASE; ANDROGEN; ANDROGEN RECEPTOR; ARSENIC; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROSTATE SPECIFIC ANTIGEN; RAS PROTEIN; TRANSCRIPTION FACTOR ELK 1;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL TRANSFORMATION; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANDROGENS; ARSENIC; BLOTTING, WESTERN; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; ENVIRONMENTAL POLLUTANTS; EPITHELIAL CELLS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; PROSTATE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); RAF KINASES; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33847055846     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.9630     Document Type: Article

References (50)

1. Achanzar WE, Brambila EM, Diwan BA, Webber MM, Waalkes MP. 2002. Inorganic arsenite induced malignant transformation of human prostate epithelial cells. J Natl Cancer Inst 94(24):1888-1891.
2. Ady N, Morat L, Fizazi K, Soria J-C, Mathieu M-C, Prapotnich D, et al. 2004. Detection of HER 2/neu positive circulating epithelial cells in prostate cancer patients. Br J Cancer 90(2):443-448.
3. Arnold JT, Isaacs JT. 2002. Mechanisms involved in the progression of androgen independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 9(1):61-73.
4. Bakin RE, Gioeli D, Bissonette EA, Weber MJ. 2003a. Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res 63(8):1975-1980.
5. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. 2003b. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 63(8):1981-1989.
6. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. 1997. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18(6):1215-1223.
7. Benbrahim-Tallaa L, Waterland RA, Styblo M, Achanzar WE, Webber MM, Waalkes MP. 2005a. Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation. Toxicol Appl Pharmacol 206(3):288-298.
8. Benbrahim-Tallaa L, Webber MM, Waalkes MP. 2005b. Acquisition of androgen independence by human prostate epithelial cells during arsenic-induced malignant transformation. Environ Health Perspect 113:1134-1139.
9. Carles J, Lloreta J, Salido M, Font A, Suarez M, Baena V, et al. 2004. Her-2/neu expression in prostate cancer: a dynamic process? Clin Cancer Res 10(14):4742-4745.
10. Chen CJ, Wang CJ. 1990. Ecological correlation between arsenic levels in well water and age adjusted mortality from malignant neoplasms. Cancer Res 50(17):5470-5474.
11. Craft N, Shostak Y, Carey M, Sawyers CL. 1999. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5(3):280-285
12. Crawford ED. 2003. Epidemiology of prostate cancer. Urology 62(suppl 1):3-12.
13. Culig Z. 2004. Androgen receptor cross-talk with cell signaling pathways. Growth Factors 22(3):179-184.
14. Culig Z, Bartsch G. 2006. Androgen axis in prostate cancer. J Cell Biochem 99(2):373-381.
15. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. 1994. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54(20):5474-5478.
16. Deutsch E, Maggiorella L, Eschwege P, Bourhis J, Soria JC, Abdulkarim B. 2004. Environmental, genetic, and molecular features of prostate cancer. Lancet Oncol 5(5):303-313.
17. Feldman BJ, Feldman D. 2001. The development of androgen-independent prostate cancer. Nat Rev Cancer 1(1):34-45.
18. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr. Weber MJ. 1999. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59(2):279-284.
19. Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E et al. 1999. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 5(10):2891-2898.
20. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, et al. 1998. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 58(24):5718-5724.
21. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. 2001. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61(7):2892-2898.
22. Hoa M, Davis SL, Ames SJ, Spanjaard RA. 2002. Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma. Cancer Res 62(24):7154-7156.
23. IARC (International Agency for Research on Cancer). 2004. Some Drinking Water Disinfectants and Contaminants, Including Arsenic. IARC Monogr Eval Carcinog Risk Hum 84:269-477.
24. Ilagan R, Zhang LJ, Pottratz J, Le K, Salas S, Iyer M, et al. 2005. Imaging androgen receptor function during flutamide treatment in the LAPC9 xenograft model. Mol Cancer Ther 4(11):1662-1669.
25. Kim J, Coetzee GA. 2004. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 93(2):233-241.
26. Kyprianou N, Isaacs JT. 1988. Activation of programmed cell death in the rat ventral prostate. Endocrinology 122(2):552-562.
27. Lee EC, Tenniswood MP. 2004. Emergence of metastatic hormone-refractory disease in prostate cancer after anti-androgen therapy. J Cell Biochem 91(4):662-670.
28. Lewis DR, Southwick JW, Ouellet-Hellstrom R, Rench J, Calderon RL. 1999. Drinking water arsenic in Utah: a cohort mortality study. Environ Health Perspect 107:359-365.
29. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessellac RL, Visakorpi T. 2001. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61(9):3550-3555.
30. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JL, Isaacs WB, et al. 1992. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 89(14):6319-6323.
31. NRC (National Research Council). 1999. Arsenic in Drinking Water. Washington, DC:National Academy Press.
32. NTP. 2000. Reports on Carcinogens. First and Subsequent 2nd-9th (1980-2000). Research Triangle Park, NC:National Toxicology Program.
33. Ren SH, Wang JW, Zhang L. 2005. Effects of Her-2/neu siRNA-mediated gene silencing on cell cycle and apoptosis of lung adenocarcinoma cells. Zhonghua Yi Xue Za Zhi 85(22):1530-1534.
34. Rizos E, Sourvinos G, Arvanitis DA, Velegrakis G, Spandidos DA. 1999. Low incidence of H-, K- and N- ras oncogene mutations in cytological specimens of laryngeal tumours. Oral Oncol 35(6):561-563.
35. Sadar MD, Hussain M, Bruchovsky N. 1999. Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer 6(4):487-502.
36. Shi Y, Chatterjee SJ, Brands FH, Shi SR, Pootrakul L, Taylor CR, et al. 2006. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. BJU Int 97(1):170-178.
37. Sugita S, Kawashima H, Tanaka T, Kurisu T, Sugimura K, Nakatani T. 2004. Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor. Oncol Rep 11(6):1273-1279.
38. Tan J-A, Sharief Y, Hamil KG, Gregory CW, Zang D-Y, Sar M, et al. 1997. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11(4):450-459.
39. Taplin ME, Balk SP. 2004. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91(3):483-490.
40. Veeramani S, Yuan TC, Chen SJ, Lin FF, Petersen JE, Shaheduzzaman S, et al. 2005. Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr Relat Cancer 12(4):805-822.
41. Webber MM, Bello D, Kleinman HK, Hoffman MP. 1997. Acinar differentiation by nonmalignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis 18(6):1225-1231.
42. Weber MJ, Gioeli D. 2004. Ras signaling in prostate cancer progression. J Cell Biochem 91(1):13-25.
43. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, et al. 2000. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60(24):6841-6845.
44. Westin P, Bergh A. 1998. Apoptosis and other mechanisms in androgen ablation treatment and androgen independent progression of prostate cancer. Cancer Detect Prev 22(5):476-484.
45. Wu HC, Hsieh JT, Gleave ME, Brown NM, Patha S, Chung LW. 1994. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 57(3):406-412.
46. Wu MM, Kuo TL, Hwang YH, Chen CJ. 1989. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol 130(6):1123-1132.
47. Wu Y, Soslow RA, Marshall DS, Leitao M, Chen B. 2004. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol Oncol 95(3):570-575.
48. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. 1999. From HER2/neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96(10):5458-5463.
49. Yu M, Leav BA, Leav I, Merk FB, Wolfe HJ, Ho SM. 1993. Early alterations in ras protooncogene mRNA expression in testosterone and estradiol-17 beta induced prostatic dysplasia of Noble rats. Lab Invest 68(1):33-44.
50. Zhau HE, Wan DS, Zhou J, Miller GJ, von Eschenbach AC. 1992. Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol Carcinog 5(4):320-327.